强 生 Cordis 学 院 Cordis 百家病例论坛 PCI for patients with Chronic Renal Dysfunction Dr. Liyi First Affiliated Hospital of Sun Yat-sen University.

Slides:



Advertisements
Similar presentations
Prevention of Contrast-Induced Nephropathy (CIN) Sepehr Khashaei, MD Assistant professor Department of Internal Medicine.
Advertisements

Journal Club Rakesh Latchamsetty October 5, 2007.
Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
Managing T2DM during Ramadan Dr. Asrar Said Hashem Specialist in Internal Medicine (Al-Amiri Hospital) Fellow of KIMS Endocrine, Diabetes and Metabolism.
REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.
Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven.
Efficacy of Sodium Bicarbonate Infusion in Reversal of Acute Renal Failure 1 NEPHRO 2014 June 25-28, 2014 Valencia, Spain.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
Heart Failure with Normal Systolic Function: Better or Worse Prognosis? Maria Rosa Costanzo, M.D., F.A.C.C, F.A.H.A. Medical Director, Midwest Heart Specialists.
Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Early high-dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome The PRATO-ACS (Protective effect of Rosuvastatin and.
Contrast Induced Nephropathy: Predictors, Prevention, and Management Columbia University Medical Center Cardiovascular Research Foundation Roxana Mehran,
Update Lipid Management in Chronic Kidney Disease 成大醫院心臟內科 李政翰醫師 助理教授.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
臨床藥事照護 年 09 月其他之用藥建議 疑問藥物問題內容後續追蹤 Actein qid 2 包非正常使用 dose FOR CKD 病人的腎臟 保護 2 文獻資料資料來源 Prophylactic oral administration of the antioxidant.
New guidelines for CABG
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
Hepatorenal Syndrome Dr Allister J Grant Leicester Liver Unit
A Prospective Randomized Trial of Furosemide-Induced High-Volume Diuresis with Matched Hydration Using a Dedicated Device to Prevent Contrast Nephropathy.
REMEDIAL II REnal Insufficiency Following Contrast MEDIA Administration II TriaL RenalGuard system in high risk patients for contrast induced acute kidney.
Radiocontrast Nephropathy Jason S. Finkelstein, M.D. Tulane University HSC Division of Cardiology 3/2/04.
Antiplatelet Therapy in Renal Dysfunction Moderator E. Magnus Ohman, MD Professor of Medicine Director Program for Advanced Coronary Disease Duke University.
ARMYDA-CIN Trial [Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy]
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
CARE Cardiac Angiography in REnally impaired patients: A comparison between Iodixanol (Visipaque) and Iopamidol (Isovue) in high risk patients for contrast.
Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
COOL RCN A Prospective, Randomized Trial Examining the Safety and Efficacy of Systemic Hypothermia for the Prevention of Radiocontrast Nephropathy Gregg.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
OVERALL SURVIVAL Adapted from Scandinavian Simvastatin Survival Study Group Lancet 1994;344: % of patients alive Simvastatin (n=2221)
Bicarbonate-Based Solutions in the Management of Acute Kidney Injury Vania Cecilia Prudencio-Ribera, MD 1 ; Universidad Mayor de San Simón, School of Medicine,
Gestione dell’insufficienza renale nelle sindromi coronariche: prima e dopo lo studio emodinamico Rossana Fusco Dipartimento Cardio-Toraco-Vascolare A.De.
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.
Prevention of Serious Adverse Outcomes Following Angiography (PRESERVE) Trial Steven D. Weisbord MD, MSc.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Acetylcysteine for the prevention of Contrast- induced nephropaThy (ACT) Trial: The ACT Trial Investigators Presenter: Otavio Berwanger (MD; PhD) Chair.
Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary.
A.Rasoolzadeh MD. Contrast induced nephropathy (CIN): A kind of reversible AKI as a rise in serum creatinine (by 25%) during of h after receipt.
Did I do that? Drug-Induced Acute Kidney Injury Krista Rieger, PharmD, BCPS PGY2 Internal Medicine Resident.
Special Situations In The Management Of In-Patient Hyperglycemia
Sodium Bicarbonate therapy for Prevention of contrast induced nephropathy of contrast induced nephropathy -A Meta-analysis American Journal of Kidney Diseases,
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.
CONTRAST NEPHROPATHY MARC J. SCHWEIGER Director Cardiac Catheterization Laboratories, Baystate Medical Center.
Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med.
1 CONTRAST - INDUCED ACUTE RENAL INJURY. Acute Renal Failure Nephrotoxic ATN Endogenous Toxins –Heme pigments (myoglobin, hemoglobin) –Myeloma light chains.
Hydration for Contrast-Induced Acute Kidney Injury (CI-AKI) Prevention
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Clinical Outcomes with Newer Antihyperglycemic Agents
TAVR in Patients With Chronic Kidney Disease
Roxana Mehran, MD Consulting Fees Abbott Vascular Regado BioSciences
Clinical Outcomes with Newer Antihyperglycemic Agents
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Prevention of contrast induced nephropathy
Early high-dose Rosuvastatin for
Contrast Awareness: Why and When Do we Worry?
Clinical Research at the VA
VA Cooperative Studies Program Trial # 578
Excessively High Hydration Volume May Not Be Associated With Decreased Risk of Contrast‐Induced Acute Kidney Injury After Percutaneous Coronary Intervention.
Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes After Percutaneous Coronary Intervention: A Subgroup analysis of the Prevention.
Renal Pharmacy Group Beginners Lectures 2018
Hexabrix Key Clinical Review Mehran, 2009
Bệnh thận do thuốc cản quang
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
Presentation transcript:

强 生 Cordis 学 院 Cordis 百家病例论坛 PCI for patients with Chronic Renal Dysfunction Dr. Liyi First Affiliated Hospital of Sun Yat-sen University

强 生 Cordis 学 院 Cordis 百家病例论坛 With the aging of society and development of PCI techniques, we are facing more and more CAD patients with CRD Our hospital has a very large hemodialysis and peritoneal dialysis center, we are facing more and more CRD patients Serum creatine level is a very poor indicator for patient’s renal function Depleted renal function means poor prognosis

强 生 Cordis 学 院 Cordis 百家病例论坛 Szczech L. et al., Circulation 2002; 105: With DM or CKD (n=2921) With DM, without CKD (n=611) Without DM, with CKD (n=46) With both DM and CKD (n=30) 95% 85% 77% 54% * CKD defined as baseline Cr > 1.5 mg/dl Freedom from Cardiac Death for Patients with CKD* and Diabetes (DM) BARI Trial + Registry

强 生 Cordis 学 院 Cordis 百家病例论坛 DM, <25% creatinine increase No DM, <25% creatinine increase DM,  25% creatinine increase No DM,  25% creatinine increase 0 0% 20% 40% 60% 80% 100% Time (Months) Event-Free Survival 80% 80% 64% 55% CIN After PCI: 1-Year Event-Free Survival Cr. Increase & DM Gruberg, et al. JACC 2000; 36:

强 生 Cordis 学 院 Cordis 百家病例论坛 The best strategies is to nip CIN in the bud So… who are at the high risk ?

强 生 Cordis 学 院 Cordis 百家病例论坛 Risk Factors for CIN Patient-related Risk Factors Renal insufficiency Renal insufficiency Diabetes mellitus with renal insufficiency Diabetes mellitus with renal insufficiency Age Age Volume depletion Volume depletion Hypotension Hypotension Low cardiac output Low cardiac output Class IV CHF Class IV CHF Other nephrotoxins(NSAIDs) Other nephrotoxins(NSAIDs) Renal transplant Renal transplant Hypoalbuminemia (<35 g/L) Hypoalbuminemia (<35 g/L) Procedure-related Risk Factors Multiple contrast media injection within 72 hrs Multiple contrast media injection within 72 hrs Intra-arterial injection site Intra-arterial injection site High volume of contrast media High volume of contrast media High osmolality of contrast media High osmolality of contrast media

强 生 Cordis 学 院 Cordis 百家病例论坛 Risk of CIN Relation to Baseline Creatinine Davidson et al. Annals Int Med (1989) Baseline Serum Creatinine(mg/dl) Probability of Nephrotoxicity (%)

强 生 Cordis 学 院 Cordis 百家病例论坛 Prediction of CIN and Dialysis After PCI Independent risk factors: CrCl>>Diabetes>>Contrast Volume PCI, percutaneous coronary intervention. Data adapted from: Berns AS. Kidney Int. 1989;36(4):730–740; McCullough PA. Am J Med. 1997;103:386–375; Rihal et al. Circulation. 2002;105:2259–2264. Mean age=65 years, 72 kg man Calculated CrCl (mL/min) Renal Event Rate (%) No diabetics Diabetics n=424 n=3695 n=7586 CIN Dialysis CrCl ~ 30 mL/min 30–40% CIN rate CrCl ~ 30 mL/min 30–40% CIN rate

强 生 Cordis 学 院 Cordis 百家病例论坛 CIN: Incidence & Risk Factors Contrast dose Diabetes < Cr Clearance PCIOR Predictors of ARF +Dialysis 1,826 consecutive pts undergoing PCI: CIN without dialysis occurred 14.5% CIN with dialysis occurred 0.8% McCullough, et al. Am J Med 1997; 103: 375

强 生 Cordis 学 院 Cordis 百家病例论坛

强 生 Cordis 学 院 Cordis 百家病例论坛 Be aware of small body weight old ladies eg. Female, Scr = 80 umol/L, age =60, wt = 60kg  CCr = 62.4 ml/min Wt = 60kgAge = 60 AgeCCrWtCCr if. Female, Scr = 80 umol/L, age = 80, wt = 45kg  CCr = 35.1 ml/min

强 生 Cordis 学 院 Cordis 百家病例论坛 or or 8 CIN Risk Score P<.0001 χ 2 by trend Mehran R et al. J Am Coll Cardiol. 2003;41:37A. A Risk Score for Prediction of CIN Multivariate Predictors Diabetes – any Tx Age over 70 SVG treated Multiple vessels treated Female IABP use Acute coronary syndrome CrCl <50 mL/min

强 生 Cordis 学 院 Cordis 百家病例论坛 Risk Score Risk of CIN Risk of Dialysis ≤ 57.5%0.04% 6 to %0.12% 11 to %1.09% ≥ %12.6% Mehran et al. JACC 2004;44: Hypotension IABP CHF Age >75 years Anemia Diabetes Contrast media volume Risk Factors Integer Score 1 for each 100 cc 3 Scheme to define CIN risk score Serum creatine > 1.5mg/dl4 eGFR <60ml/min/1.73 m 2 2 for 40 – 60 4 for 20 – 40 6 for < 20 eGFR < 60ml/min/1.73 m 2 = 186 x (SCr) x (Age) X (0.742 if female) x (1.210 if African American) Calculate OR

强 生 Cordis 学 院 Cordis 百家病例论坛 How to prevent … Minimize Contrast dosage Hydration N-AC Type of Contrast Media ?

强 生 Cordis 学 院 Cordis 百家病例论坛 Minimize Contrast Dosage My Tips Staged procedure Use your syringe wisely Plan twice, inject once Diluted contrast for visualization vessels Use roadmap wisely Use your flat panel DSA wisely

强 生 Cordis 学 院 Cordis 百家病例论坛 Hydration

强 生 Cordis 学 院 Cordis 百家病例论坛 Prevention of CIN: Hydration Solomon, et al. NEJM 1994; 331: % 10% 20% 30% 40% 50% 60% Saline Saline + Mannitol Saline + Furosemide Non-DM DM % CIN 78 Pts with CRI (Cr mg/dl) IV Fluids: 1/2 1ml/kg/hr for 12 hr before & after contrast Mannitol: 50 g 1 hr before contrast Furosemide: 80 mg IV 30 min before contrast 78 Pts with CRI (Cr mg/dl) IV Fluids: 1/2 1ml/kg/hr for 12 hr before & after contrast Mannitol: 50 g 1 hr before contrast Furosemide: 80 mg IV 30 min before contrast 7% 14% 17% 38% 36% 43%

强 生 Cordis 学 院 Cordis 百家病例论坛 Sodium Bicarbonate Shea E. Hogan et al. AHJ 2008;156:414

强 生 Cordis 学 院 Cordis 百家病例论坛 Question remaining in hydration When ? What ? How many ? How ?

强 生 Cordis 学 院 Cordis 百家病例论坛 N-ACETYLCYSTEINE (NAC) ?

强 生 Cordis 学 院 Cordis 百家病例论坛 Meta-analysis: NAC Randomized, 13 Controlled Trials : N=1882 Zagler A, et al. AHJ 2006;151:140

强 生 Cordis 学 院 Cordis 百家病例论坛 Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy Kelly, A. M. et. al. Ann Intern Med 2008;148:

强 生 Cordis 学 院 Cordis 百家病例论坛 Contrast Agent – remaining questions Iso-osmolarity vs. Low osmolarity

强 生 Cordis 学 院 Cordis 百家病例论坛 My protocol in dealing high risk patients Identify high risk patients Take preventive measures Check Scr before and after procedure

强 生 Cordis 学 院 Cordis 百家病例论坛

强 生 Cordis 学 院 Cordis 百家病例论坛

强 生 Cordis 学 院 Cordis 百家病例论坛 Patients Characteristics Male, 65yrs Exertional angina for 1 weeks History: DM (on oral medication) dyslipidemia, Hypertension Lab. Exam: LDL: 3.1 mmol/L TNT: 1.1 ng/ml SCr: 135 umol/L

强 生 Cordis 学 院 Cordis 百家病例论坛 Risk Assessment CCr: 44 ml/min Diabetes – any Tx Acute coronary syndrome CrCl <50 mL/min

强 生 Cordis 学 院 Cordis 百家病例论坛 Preventive measures Hydration N-AC Change oral hypoglycemic into insuline Patients and family consent Baseline SCr: 135umol/L

强 生 Cordis 学 院 Cordis 百家病例论坛

强 生 Cordis 学 院 Cordis 百家病例论坛

强 生 Cordis 学 院 Cordis 百家病例论坛

强 生 Cordis 学 院 Cordis 百家病例论坛 下一步的治疗策略: 1 , LCX ; 2 , LAD ; 3 , RCA 。

强 生 Cordis 学 院 Cordis 百家病例论坛

强 生 Cordis 学 院 Cordis 百家病例论坛

强 生 Cordis 学 院 Cordis 百家病例论坛

强 生 Cordis 学 院 Cordis 百家病例论坛 Follow-up D2 Scr: 128 umol/L D3 Scr: 130 umol/L

强 生 Cordis 学 院 Cordis 百家病例论坛 谢谢!